SOURCE: Barrier Therapeutics, Inc.

December 06, 2006 18:42 ET

Barrier Therapeutics to Participate in the 2006 RBC Capital Markets Healthcare Conference

PRINCETON, NJ -- (MARKET WIRE) -- December 6, 2006 --Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer, is scheduled to participate on the panel entitled "Skin Deep: The Future of Clinical Dermatology," being held at the 2006 RBC Capital Markets Healthcare Conference on Wednesday, December 13, 2006, beginning at 1:30 p.m. Eastern Standard Time. The conference will be held at The Westin New York at Times Square in New York City on December 13 and 14, 2006.

The panel discussion will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. A replay of the webcast will be available for 30 days.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202